FDA · United States
glycopyrronium tosylate — FDA regulatory status
glycopyrronium tosylate (GLYCOPYRRONIUM TOSYLATE) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- GLYCOPYRRONIUM TOSYLATE
- Mechanism
- Muscarinic acetylcholine receptor inhibitor
- Target
- Muscarinic acetylcholine receptor
- Structured fields
- 7
Pharmacology context used for competitive intelligence: Muscarinic acetylcholine receptor inhibitor. Target: Muscarinic acetylcholine receptor. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 1 published clinical program and 4 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Glycopyrronium | Approved | Chinese Academy of | NCT05265507 |
Related patents
Related hubs
FAQ
What is the FDA approval status of glycopyrronium tosylate?
glycopyrronium tosylate currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get glycopyrronium tosylate regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to glycopyrronium tosylate?
This spoke lists 1 published program associated with glycopyrronium tosylate in our pipeline index.